By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today reported that its nine-month revenues declined 58 percent from the comparable period in 2009.

The Berlin, Germany-based molecular diagnostics developer reported total revenues of €1.3 million ($1.8 million) for the first nine months of 2010, a sharp drop from €3.2 million for the first nine months of 2009. The firm said that the 2009 period included non-recurring payments from R&D and licensing partnerships.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.